Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

COCP Cocrystal Pharma Inc

1,90

0,00 (0,00%)

Nach Börsenschluss

Zuletzt aktualisiert: 22:02:01

Verzögert um 15 Minuten

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Cocrystal Pharma Charts.

Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Cocrystal Pharma Charts.

News Cocrystal Pharma Inc

Form 8-K - Current report
Montag 13 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Montag 13 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Montag 13 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Form DEF 14A - Other definitive proxy statements
Dienstag 7 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
Mittwoch 1 Mai 2024 (3 Wochen vor) • GlobeNewswire Inc.

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
Donnerstag 28 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
Dienstag 19 März 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Freitag 1 März 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Montag 8 Januar 2024 (4 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 4 Januar 2024 (5 Monate vor) • Edgar (US Regulatory)

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
Donnerstag 4 Januar 2024 (5 Monate vor) • GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Dienstag 2 Januar 2024 (5 Monate vor) • Edgar (US Regulatory)

Weitere Cocrystal Pharma Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen